Pliant Therapeutics to present PLN-101095 trial data at ASCO meeting

Pliant Therapeutics

Pliant Therapeutics

PLRX

0.00
  • Pliant Therapeutics will present data on PLN-101095 in combination with pembrolizumab at the ASCO Annual Meeting in Chicago, May 29 to June 2, 2026.
  • The poster is scheduled for Saturday, May 30, 2026, 1:30 p.m. to 4:30 p.m. Central Time, in the Developmental Therapeutics – Immunotherapy session.
  • The presentation focuses on cohort expansion from the Phase 1 study in patients with advanced solid tumors refractory to immune checkpoint inhibitors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211729PRIMZONEFULLFEED9725072) on May 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.